Drug intelligence / Profile preview

methylergometrine

Development stage
Approved
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Methylergometrine (also known as methylergonovine) is a semi-synthetic ergot alkaloid used primarily in obstetrics to prevent or treat postpartum hemorrhage and uterine atony. It acts as a potent uterotonic by directly stimulating the smooth muscle of the uterus, increasing tone, rate, and amplitude of contractions, thereby reducing blood loss after childbirth or abortion. It is also sometimes used for the prevention and acute treatment of migraine headaches. The drug can be administered orally, intramuscularly, or intravenously. At high doses it may produce psychedelic effects similar to LSD due to its structural similarity as an ergoline derivative[1][2][5]. Methylergometrine is on the World Health Organization's List of Essential Medicines[5].

Brand names
Methergine
Other names
methylergonovine maleate甲麦角新碱N-[alpha-(Hydroxymethyl)propyl]-D-lysergamidePartergin
02

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1E (5-hydroxytryptamine receptor 1E)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1A (α1A)DRD1 (Dopamine D1 Receptor)HTR1F (Serotonin 5-HT1F receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)DRD2 (Dopamine D2 Receptor)HTR7 (5-hydroxytryptamine receptor 7)HTR5A (Serotonin Receptor 5A)HTR1B (5-Hydroxytryptamine Receptor 1B)

Beyond the preview

Go deeper on methylergometrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylergometrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call